Article
Evaluation of two, commercial, multi-dye, nucleic acid amplification technology tests, for HBV/HCV/HIV-1/HIV-2 and B19V/HAV, for screening blood and plasma for further manufacture.
Vox sanguinis - 1 Jan 2013
Müller M M, Fraile M I G, Hourfar M K, Peris L B, Sireis W, Rubin M G, López E M, Rodriguez G T, Seifried E, Saldanha J, Schmidt M
Abstract excerpt
BACKGROUND: The cobas TaqScreen MPX Test, version 2.0, a multiplex, multi-dye nucleic acid amplification technology (NAT) test from Roche was evaluated by two European Blood Banks, the German Red Cross Blood Donor Service, Frankfurt, Germany and Centro de Hemoterapia y Hemodonación de Castilla y León, Valladolid, Spain. In addition, the cobas TaqScreen DPX Test was evaluated for the simultaneous detection and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.